Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-technology-1/oncogenex-reports-third-quarter-2009-financial-results-14740-8/;/a> ) was not found.

Search biology technology 1 oncogenex reports third quarter 2009 financial results 14740 8 ; a>  at Google

Search biology technology 1 oncogenex reports third quarter 2009 financial results 14740 8 ; a>  at Yahoo

Search biology technology 1 oncogenex reports third quarter 2009 financial results 14740 8 ; a>  at Msn

Google
 
Breaking Biology News(10 mins):H1N1 influenza adopted novel strategy to move from birds to humans 2H1N1 influenza adopted novel strategy to move from birds to humans 3H1N1 influenza adopted novel strategy to move from birds to humans 4Superior offspring without genetic modification 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Microbix Biosystems Provides a Corporate Update 14649 1Microbix Biosystems Provides a Corporate Update 14649 2Microbix Biosystems Provides a Corporate Update 14649 3Microbix Biosystems Provides a Corporate Update 14649 4Microbix Biosystems Provides a Corporate Update 14649 5Microbix Biosystems Provides a Corporate Update 14649 6Microbix Biosystems Provides a Corporate Update 14649 7Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9 000 Patients Annually 5846 1Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9 000 Patients Annually 5846 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9 000 Patients Annually 5846 3PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 1PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 2PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 3PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 4PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 5PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 6PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 7PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 8PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 9PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 10
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 1Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 2Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 3Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 4Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 1Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 2Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 3Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 4Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 6Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 7Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 8Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 9Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 10Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 11Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 12Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 13Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 14Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 15Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 16Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 17Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 18Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 19Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 20Geneticists hunt for scleroderma triggers 60340 1Geneticists hunt for scleroderma triggers 60340 2